Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada.

ABSTRACT:

Background

Ofatumumab is a high-efficacy disease-modifying therapy (DMT) approved for first-line treatment of relapsing-remitting multiple sclerosis (RRMS) in Canada.

Objective

The aim of this study was to evaluate the cost effectiveness of ofatumumab from a Canadian healthcare system perspective.

Methods

A Markov cohort model was run over 65 years using annual cycles, 1.5% annual discount rate, and 100% treatment discontinuation at 10 years. The British Columbia database informed natural history transition probabilities. Treatment efficacy for DMTs were sourced from a network meta-analysis. Clinical trial data were used to estimate probabilities for treatment-related adverse events. Health utilities and costs were obtained from Canadian sources (if available) and the

SUBMITTER: Baharnoori M 

PROVIDER: S-EPMC9596641 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature